Background: Although many studies have assessed cognitive functioning in first-episode schizophrenia (FESz), the pattern and severity of impairment across cognitive domains remain unclear. Moreover, few studies have directly compared the pattern of cognitive performance between FESz and chronic schizophrenia (CSz). In this study we examined the cognitive impairment profile in FESz using a standardized neurocognitive battery (MATRICS Consensus Cognitive Battery; MCCB). Methods: MCCB data were compared from 105 FESz patients, 176 CSz patients and 300 non-psychiatric (NP) participants. Mixed model analysis evaluated group differences in MCCB profiles and relative strengths and weaknesses in the MCCB profiles of patients. Clinical implications of MCCB performance were also examined; we compared the proportion of participants from each group who exhibited clinically-significant global cognitive impairment based on the MCCB Overall Composite score. Results: FESz and CSz showed impaired performance across all MCCB domains relative to NP. With the exception of relative preservation of working memory and social cognition in FESz, the MCCB domain scores were similar in FESz and CSz. The distribution of impairment on the Overall Composite score did not significantly differ between FESz and CSz; compared to NP, both patient groups were overrepresented in moderate and severe impairment categories. Conclusion: The pattern, magnitude, and distribution of severity of impairment in FESz were similar to that observed in CSz. However, early in the illness, there may be relative sparing of working memory and social cognition.
Introduction
Marked cognitive impairment is a core, enduring feature of schizophrenia, prompting some researchers to posit that the illness can be conceptualized as primarily a disorder of cognition (Rund, 1998; Green and Nuechterlein, 1999) . Among patients with chronic schizophrenia (CSz), cognitive impairment is diffuse and pervasive, with deficits typically 1 to 2 standard deviations below non-psychiatric control samples across various cognitive domains (Heinrichs and Zakzanis, 1998; Gold, 2004; Green, 2006) . Cognitive impairment appears to be a relatively stable feature of schizophrenia (Hoff et al., 2005; Barder et al., 2013b) , even across acute vs. remitted states (Nuechterlein et al., 1992) , with limited response to antipsychotic treatment (Rund, 1998; Keefe et al., 2007) . Cognitive impairment is present in firstepisode schizophrenia (FESz; Gold et al., 1999; Hoff et al., 1999; Mohamed et al., 1999; Addington and Addington, 2002; Barder et al., 2013a) , and likely precedes the onset of illness in an attenuated form (Cornblatt et al., 1999; Hawkins et al., 2004; Lencz et al., 2006; Simon et al., 2007; Seidman et al., 2010; Lewandowski et al., 2011) . However, the findings have been mixed regarding the magnitude of cognitive impairment in FESz compared to CSz, with some studies reporting negligible differences between FESz and CSz (e.g., Hoff et al., 1992) , and others reporting less impairment in FESz relative to CSz, at least on some cognitive tests (e.g., Saykin et al., 1994; Albus et al., 1996; Addington and Addington, 2002; Townsend and Norman, 2004; Braw et al., 2008) . Hence, the pattern and severity of impairment in FESz across cognitive domains remain unclear.
A meta-analysis of 43 studies of cognition in FESz (Mesholam-Gately et al., 2009 ) provided strong evidence for notable impairment across all cognitive domains, with medium to large mean effect sizes on par with those reported in CSz (Heinrichs and Zakzanis, 1998) . Impairment was most pronounced in immediate verbal memory and processing speed, in addition to the global impairment observed in schizophrenia. Indeed, a selective deficit of verbal memory and processing speed has been reported elsewhere in the schizophrenia literature (e.g., Dickinson et al., 2008; Gonzalez-Blanch et al., 2010) . The meta-analysis noted significant heterogeneity of effect sizes within cognitive domains and between studies, likely due to methodological variations across studies, such as differences in the operational definition of FESz, properties of the patient samples (e.g., diagnoses, demographic variables), medications, and possible cohort effects. Inconsistency in cognitive test batteries across studies provides an additional source of variability in that tests may differ substantially in reliability, which impacts estimates of effect size (Baugh, 2002) . Moreover, given that the various tests were not normed on the same sample, it is difficult to directly compare differences in effect sizes across tests/domains (Russell et al., 2005) .
The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB; Nuechterlein and Green, 2006 ) is a compilation of independently owned and published tests that initially had normative data from nonoverlapping samples. The MCCB has the advantage of being co-normed (i.e., normative data for each test collected from the same sample) on the non-psychiatric (NP) community sample from the MATRICS Psychometric and Standardization Study (MATRICS PASS; Kern et al., 2008) . The MCCB includes seven cognitive domains: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. A brief description of the 10 tests comprising the MCCB can be found in Table 1 . Five MCCB domains are assessed with one test each, thus the T-score and percentile for those domains are based on those individual tests. The speed of processing and working memory domains are assessed with multiple tests, and these domain scores are based on a composite of the included tests. In addition to the seven domain scores, the MCCB also provides an Overall Composite score, an index of cognitive functioning across domains. The Overall Composite score is derived through equal weighting of the seven MCCB domain scores (Nuechterlein and Green, 2006) .
The profile of MCCB impairment for a CSz sample was previously reported (Kern et al., 2011) . Compared to the NP sample, CSz patients were impaired across all MCCB domains, with greater relative impairment in speed of processing and working memory, and less relative impairment in reasoning and problem solving compared to their average performance across the remaining MCCB domains.
Adoption of the MCCB as a neuropsychological test battery in schizophrenia research is on the rise. At the time of this writing, ClinicalTrials.gov, an online registry of clinical trials across the globe maintained by the National Institutes of Health and National Library of Medicine, lists over 50 studies that employ the MCCB. The aim of this paper was to examine the overall magnitude and profile of cognitive impairment in FESz using the MCCB. Specifically, we compared MCCB domain scores for a FESz sample to data from CSz and NP participants in MATRICS PASS Kern et al., 2011 ). Four hypotheses were tested: 1) that FESz patients would show significant impairment averaged across MCCB domains compared to NP; 2) that FESz patients would show similar magnitude of impairment as CSz patients; 3) consistent with the Mesholam-Gately meta-analysis (MesholamGately et al., 2009) , that FESz patients would exhibit particular weakness in speed of processing and verbal learning relative to performance in the remaining MCCB domains; and 4) finally, that the proportion of participants from each patient group who exhibit clinically-significant global cognitive impairment will not differ.
Methods

Participants
Three samples of participants provided data for these analyses. The FESz sample included 105 patients from the UCLA Aftercare Research Program, an outpatient research clinic for FESz. Inclusion criteria were: 1) onset of a first psychotic episode within 24 months of program entry, 2) fulfillment of DSM-IV (American Psychiatric Association, 1994) criteria for schizophrenia, schizoaffective disorder, depressed type, or schizophreniform disorder, 3) age of 18 to 45 years, and 4) sufficient fluency in English to allow for valid completion of the testing protocol. DSM-IV diagnoses were made using the Structured Clinical Interview for DSM-IV (SCID; First et al., 2001 ). These participants met criteria for schizophrenia (n = 56), schizoaffective disorder, depressed type (n = 13), or schizophreniform disorder (n = 36).
The other two samples were from the five academic sites (Duke University, Harvard University, University of Kansas, Maryland Psychiatric Research Center, and UCLA) in MATRICS PASS Kern et al., 2011) . The CSz sample included 176 patients with a DSM-IV diagnosis of schizophrenia (n = 151) or schizoaffective disorder, depressed type (n = 25). Inclusion criteria were: 1) a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, depressed type, based on SCID interview, 2) age 18-65 years, and 3) clinical stability as indicated by stable outpatient or rehabilitation center status and no medication changes in month prior to testing. The NP sample included 300 community residents aged 20-59, representative of the 2000 U.S. Census with respect to gender, race, ethnicity, and level of education.
Patients with a diagnosis of schizoaffective disorder, depressed type were included in these analyses because previous research suggests that the cognitive impairments associated with that diagnosis are comparable with those observed in schizophrenia (Bora et al., 2009; Simonsen et al., 2011) . Exclusion criteria for all participants were: 1) history of neurological disorder or head injury, 2) IQ less than 70 or evidence of pervasive developmental disorder, 3) alcohol or substance abuse (1 month prior to testing) or dependence (6 months prior to testing) and/or excessive lifetime use of alcohol or substances, and 4) use of any medications that could interfere with test performance. In addition, for NP participants, history of schizophrenia or any other psychotic- spectrum disorder was exclusionary. Exclusion criteria were minimal in an effort to avoid creating a "super normal" comparison sample (Kendler, 1990) . Informed consent was obtained from all participants using forms approved by the local IRBs. Demographic information for all participants and clinical information for patient participants can be found in Table 2 . FESz patients were substantially younger than CSz patients. As is typical, the two patient groups included more males than females in contrast to the stratified NP sample. All analyses of MCCB scores use age and gender correction based on the MCCB computer scoring program. The groups also differed in terms of race and ethnicity: compared to the NP sample, both patient groups had a lower proportion of Caucasians and a higher proportion of African Americans. In addition, the FESz sample had a higher proportion of Asian/Pacific Islanders and individuals of Hispanic ethnicity. Using the method of Andreasen et al. (2010) , chlorpromazine (CPZ) equivalents were calculated for antipsychotic medication dosing in the patient groups. The CSz group was prescribed a significantly higher mean equivalent dose of antipsychotic medication than the FESz group. In addition, the CSz group exhibited higher levels of positive and general symptoms, as assessed with the Brief Psychiatric Rating Scale (BPRS; Ventura et al., 1993) ; the two patient groups did not differ on the level of negative symptoms.
Procedure
FESz patients completed the MCCB (Nuechterlein and Green, 2006) as part of their baseline assessment. FESz patients were prescribed risperidone, and baseline testing typically occurred within three months of outpatient program entry after medication stabilization. Testing procedures are described for the CSz sample and for the NP sample in detail elsewhere. Briefly, CSz participants were administered the beta version of the MCCB which included the 10 tests along with an additional 10 candidate tests. NP participants were administered the final version of the MCCB. For patients prescribed antiparkinsonian medication, it was discontinued (if judged clinically feasible) 48 h prior to testing to avoid anticholinergic effects on cognitive measures. Raw scores for each MCCB test were converted to age and gender corrected T-scores using the MCCB scoring program (mean = 50, s.d. = 10). For all participants, testing was conducted by bachelor's level examiners who received extensive training in administration of the MCCB. All examiners participated in a quality assurance program which included periodic checks on MCCB administration and scoring practices.
Data Analysis
A three (group) by seven (MCCB domain) mixed model analysis was conducted using IBM SPSS 21.0 Mixed Models. Follow-up analyses and contrasts were employed to decompose significant main effects and interactions. Within the mixed model analysis, follow-up single degree of freedom contrasts were conducted to examine the pattern of relative strengths and weaknesses in the MCCB profiles of the two patient groups. For each group, these contrasts compared performance on each MCCB domain with the average score on the remaining domains. MCCB Overall Composite scores were grouped by a degree of impairment based on criteria outlined by Heaton et al. (1991) for use in clinical neuropsychology: "unimpaired" (T ≥ 45), "below average" (T = 40-44), "mild impairment" (T = 35-39), "moderate impairment" (T = 20-34), and "severe impairment" (T b 20). Differences in distribution of severity of cognitive impairment across groups were assessed using chi-square analysis.
Results
Descriptive statistics
Age and gender corrected T-scores for each MCCB subtest and domain by group are presented in Table 3 . Missing data were minimal (3.5% of data points). The mixed model analyses use all available data. Calculation of the MCCB Overall Composite score was completed for subjects with complete data; the sample sizes for the MCCB Overall Composite score chi-square analysis were 99 FESz, 167 CSz, and 289 NP. 
Mixed model analysis
The MCCB profiles for each group are presented in Fig. 1 . A mixed model was fit to the data, with diagnostic group (n = 3), MCCB domain (n = 7) entered as fixed effects. The initial run of the analysis included the following variables as potential covariates: ethnicity, race, antipsychotic medication dosing (CPZ equivalents), BPRS positive symptoms, and BPRS general symptoms. Only ethnicity and race showed statistically significant fixed effects, thus, these two variables were retained as covariates in the final model. There was a significant main effect of group [F(2, 573.12 To evaluate hypotheses 2 and 3, i.e., the degree of similarity of cognitive impairment averaged across MCCB domains and MCCB performance profiles of the patient groups, a mixed model analysis was conducted comparing only the two patient groups. There was no main effect of group [F(1,275.55 . Thus, these data suggest the presence of subtle differences in the MCCB profiles for FESz and CSz: although both patient groups show significant impairment across MCCB domains compared to NP, FESz patients show mild relative sparing of working memory and social cognition compared to CSz patients.
Distribution of clinically-significant global cognitive impairment across groups
Finally, using chi-square analysis, we tested whether the distribution of impairment in the MCCB Overall Composite score differed among the three groups (see Table 4 ). The distribution pattern for the two patient groups was similar, while the distribution pattern of the NP group was significantly different from both patient groups [χ 2 (8) = 240.46, p b 0.01]. Specifically, the patient groups were overrepresented in the moderate and severe impairment categories, and underrepresented in the unimpaired category.
Discussion
Utilizing the MCCB, a cognitive battery co-normed on a nonpsychiatric (NP) community sample, we provide a profile analysis of cognitive impairment in first-episode schizophrenia. Our analyses demonstrate that the overall magnitude and pattern of cognitive impairment in FESz are similar to that observed in CSz. Both FESz and CSz evidence marked impairment across MCCB domains compared to NP. Despite the similarity of MCCB performance profiles in FESz and CSz, subtle differences were observed. Although both patient groups exhibited relative weakness in speed of processing in within group comparisons, FESz patients exhibited relative strength in working memory, while CSz patients exhibited relative weakness in this domain. Also, the working memory and social cognition scores for the FESz group were significantly higher than those of the CSz group.
These results suggest that, in addition to diffuse impairment across cognitive domains, individuals with schizophrenia show particular weakness in speed of information processing, even early in the illness. For both patient groups, speed of processing was approximately 5 Tscore points (i.e., 0.5 s.d.) below the mean performance of each group across the remaining MCCB domains. Some investigators have suggested that speed of processing underlies many of the cognitive deficits observed in schizophrenia, and serves as a rate-limiting factor for cognitive performance (e.g., Dickinson et al., 2007; Ojeda et al., 2012) . Weakness in speed of processing on the MCCB relative to the other domains has been reported elsewhere in the literature (August et al., 2012) . One possible explanation is that this finding is simply an artifact of the psychometric properties of the MCCB; the speed of processing domain is comprised of three tests and, hence, may be more reliably measured than other MCCB domains. However, while the test-retest reliability for speed of processing may be higher than that of verbal learning and visual learning, the differences between speed of processing and the remaining MCCB domains were negligible . Thus, differences in reliability across domains are unlikely to account for this pattern. Another possible explanation is increased measurement sensitivity from including multiple, imperfectly correlated measures of a domain that together sample that domain more broadly (see Kern et al., 2011) . Hence, standardized scores from domains measured by more than one test will tend to be lower than domains measured by a single test. Contrary to predictions, this FESz sample did not exhibit weakness in verbal learning relative to other domains. Perhaps the use of a word list learning task contributes to the lack of particular weakness in verbal learning on the MCCB. In the meta-analysis (Mesholam-Gately et al., 2009) , the effect size for the immediate verbal learning and memory was largest for studies that employed a test of prose (the Wechsler Memory Scale Logical Memory test, SMD = − 1.5) versus word list learning tasks (HVLT-R, SMD = −1.15).
This first-episode sample exhibited less impairment in working memory and social cognition compared to the chronic schizophrenia sample, raising the possibility that these cognitive abilities decline over the course of illness. Studies of cognition in schizophrenia have yielded inconsistent findings regarding stability versus progressive decline. Regarding working memory, some cross-sectional studies comparing FESz to CSz have reported greater impairment in CSz (Bilder et al., 1992; Lee and Park, 2005; Braw et al., 2008) . However, longitudinal studies generally report stability, or even slight improvement, in working memory over time (Albus et al., 2006; Rund et al., 2007; Gonzalez-Ortega et al., 2013; Rodriguez-Sanchez et al., 2013) . Gonzalez-Ortega et al. (2013) also found working memory to be relatively less impaired than the other cognitive domains at initial assessment and note stability over five year follow-up in FESz patients, even though there was a significant improvement in other cognitive domains. Working memory performance may be negatively impacted by illness chronicity and number of relapses (Barder et al., 2013a) .
Cross-sectional studies of social cognition suggest similar levels of impairment in FESz and CSz (Addington et al., 2006; Pinkham et al., 2007; Addington and Addington, 2008; Comparelli et al., 2011; Comparelli et al., 2013) . Regarding the MSCEIT specifically, a recent cross-sectional study demonstrated no significant difference between a FESz sample and a schizophrenia sample with a 10-12 year duration of illness on the Managing Emotions Branch (Green et al., 2012 ). In contrast, sparing of performance on the MSCEIT Managing Emotions Branch has been reported in a younger recent-onset sample (Holmen et al., 2010) . Because both the Green et al. results and the current analyses are cross-sectional in nature, they cannot rule out cohort effects. Longitudinal studies of the MCCB performance profile in FESz can more directly examine evidence for decline in working memory and social cognition over the course of illness. Longitudinal follow-up of this first-episode sample is currently underway.
Despite small differences in the MCCB profile between patient groups, the distribution of impairment on the MCCB Overall Composite score did not significantly differ between FESz and CSz. Both patient groups were over-represented in the moderately and severely impaired range, and clearly under-represented in the unimpaired range. In our sample, 59% of FESz patients exhibited moderate to severe levels of cognitive impairment (i.e., equivalent to a score of at least 1.5 standard deviations below mean NP performance) on the MCCB Overall Composite score. These results are very consistent with those reported by Rund et al. (2006) . Moreover, only 17% of FESz patients in the current sample were classified as within the unimpaired range. Thus, most schizophrenia patients present with clinically significant global impairment in cognition at illness onset.
As noted above, one limitation of this study is the cross-sectional design, which does not control for potential cohort effects. In addition, group differences on a number of clinical and demographic variables were notable for the two patient samples. However, it is important to note that the potential impact of these variables was considered in the mixed models analyses. Finally, the patient groups were not matched for age, which is difficult to avoid given that the patient groups were at different developmental stages of the illness. However, the scores Table 4 Distribution of severity of impairment on MCCB overall composite score across groups. for each MCCB domain and the Overall Composite were age and gender corrected based on the MCCB community normative sample. Longitudinal studies of cognition across phase of illness are needed to ensure that the group tendencies observed in the current study hold within subjects over time.
In sum, our analyses suggest that overall, patients early in the course of schizophrenia exhibit similar magnitude of impairment on the MCCB compared to patients with a chronic course of illness. Both patient groups exhibited marked impairment in speed of processing; however, subtle differences in the MCCB profile were observed between patient groups because of relative sparing of working memory and social cognition in FESz. Beyond this cross-sectional study, longitudinal studies of MCCB performance during the transition from early to chronic phases of schizophrenia are needed to determine whether progressive decline occurs in some cognitive domains. 
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